Medivet engaged a specialist marketing manager in September last...

Medivet engaged a specialist marketing manager in September last year. The results are starting to show with the name change to Medivet Biologics, branding of anti-cancer vaccine as K9-ACV and the new and improved web site launched in January.

https://www.linkedin.com/pub/jenny-corbin/38/b2/96a/it

There’s a clinic in upstate New York that started offering Medivet stem cell therapy in January. Perhaps of interest for Medivet followers is the clinic’s FB entry on January 6 announcing the availability of stem cell therapy. The accompanying picture shows a Medivet flyer promoting the collection and banking of stem cells at the same time as pets go in for spaying/neutering. It also gives some insight into the photogenic girl and puppy featured on the home page of the Medivet website.  

http://www.westbrookveterinaryclinic.com/stemcell.html
https://www.facebook.com/3212003514...1200351409117/323613014501184/?type=1&theater

It shouldn’t be too long before we start to value the company in terms of a more traditional PE ratio.

The two immediate prior six monthly periods saw the company go from a loss in the first half of $139K to a profit of $245K in the second half of FY2014 (giving a full year profit of $139K).

Your humble correspondent is hoping for a first half profit of around $400K. This would be a stellar result and show the company is steadily and profitably growing.

Looking forward, a (hypothetical) bottom line result of $1M over the full-year with 136M shares on issue implies a PE ratio of 13 at a 10c share price. That ratio and price would seem to represent a fairly fundamental value for the current financial year, with obviously plenty of growth potential for future years.